Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif New Formulation (REFLEXION)

Next Previous
Trial Profile

Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif New Formulation (REFLEXION)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms REFLEXION
  • Sponsors Merck KGaA; Merck Serono

Most Recent Events

  • 15 Oct 2021 Results of an analysis assessing the temporal relation between whole-brain atrophy and lesion processes presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 01 May 2020 Results, assessing data from ( REFLEX and REFLEXION) assessing pharmacodynamic biomarkers of Interferon beta 1a, presented at the 72nd Annual Meeting of the American Academy of Neurology
  • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top